{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:40Z","timestamp":1792831060864,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110635","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:23:52Z","timestamp":1791473032000},"page":"110635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of a novel BRD4 inhibitor for the treatment of acute myeloid leukemia"],"prefix":"10.1016","volume":"183","author":[{"given":"Yi-Sheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Bo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110635_bb0005","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110635_bb0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The Epigenomics of Cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110635_bb0015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110635_bb0020","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399411001992","article-title":"Bromodomains as therapeutic targets","volume":"13","author":"Muller","year":"2011","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110635_bb0025","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110635_bb0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110635_bb0035","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110635_bb0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110635_bb0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110635_bb0050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110635_bb0055","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.aaz8455","article-title":"Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation","volume":"368","author":"Gilan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110635_bb0060","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1021\/acs.jmedchem.0c00628","article-title":"Discovery of N -Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1 H -pyrrolo[2,3- c ]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain inhibitor with selectivity for the second bromodomain","volume":"63","author":"Sheppard","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110635_bb0065","unstructured":"AbbVie, A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML), clinicaltrials.gov, 2021. https:\/\/clinicaltrials.gov\/study\/NCT03360006 (accessed May 20, 2025)."},{"key":"10.1016\/j.bioorg.2026.110635_bb0070","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/acs.jmedchem.3c02104","article-title":"Discovery of novel phenoxyaryl pyridones as bromodomain and extra-terminal domain (BET) inhibitors with high selectivity for the second bromodomain (BD2) to potentially treat acute myeloid leukemia","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110635_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117752","article-title":"Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors","volume":"106","author":"Qiao","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110635_bb0080","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1021\/acs.jmedchem.2c00100","article-title":"Structure-based discovery and optimization of Furo[3,2- c ]pyridin-4(5 H)-one derivatives as potent and second bromodomain (BD2)-selective Bromo and extra terminal domain (BET) inhibitors","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110635_bb0085","doi-asserted-by":"crossref","first-page":"21577","DOI":"10.1021\/acs.jmedchem.4c02516","article-title":"Discovery of the first BRD4 second bromodomain (BD2)-selective inhibitors","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110635_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.30532","article-title":"Identification of potent BRD4-BD1 inhibitors using classical and steered molecular dynamics based free energy analysis","volume":"125","author":"Gupta","year":"2024","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2026.110635_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.chaos.2022.113061","article-title":"Integrating microsecond timescale classical and biased molecular dynamics simulations to screen potential molecules for BRD4-BD1","volume":"167","author":"Bhardwaj","year":"2023","journal-title":"Chaos, Solitons Fractals"},{"key":"10.1016\/j.bioorg.2026.110635_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116592","article-title":"Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors","volume":"55","author":"Dong","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110635_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117272","article-title":"Design, synthesis, and antitumor evaluation of triazolopyridine derivatives as novel inhibitors for BRD4","volume":"285","author":"Liu","year":"2025","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:08:25Z","timestamp":1792829305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826011715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":21,"alternative-id":["S0045206826011715"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110635","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a novel BRD4 inhibitor for the treatment of acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110635"}}